UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of **April 2021**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein are the following exhibits:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: April 19, 2021

By: /s/ Dorit Kreiner
Dorit Kreiner
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Evogene Investor Presentation.
99.2	AgPlenus Investor Presentation.
99.3	Biomica Investor Presentation.
99.4	Canonic Investor Presentation.
99.5	Lavie Bio Investor Presentation.

Exhibit 99.1


evogene
DECODING BIOLOGY
DECODING BIOLOGY
INVESTOR
PRESENTATION
Ofer Haviv, President & CEO
April 2021

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Agenda

- **Introduction**
- Fields of activity
- Main subsidiaries
- Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals




OUR VISION
Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.
DECODING BIOLOGY

Life-science product discovery & development challenges

Low probability of success with high cost and long time-to-market

Ag-chemicals Industry

Discovery and development costs of a new crop protection product



Source: Phillips McDougall, 2016

Time to develop a new crop protection product

	1995	2000	2005-8	2010-15
Number of years between the first synthesis and first sale of product	8.3	9.1	9.8	11.3

Source: Phillips McDougall, 2016

Pharmaceutical Industry

CDER'S* annual novel drug approvals: 2010-2019



Source: U.S. Food and Drug Administration

Worldwide total pharmaceutical R&D spend in 2010-2024



Source: Evaluate Pharma May 2019

*Center for Drug Evaluation and Research

The opportunity

Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product discovery & development.

When biology meets disruptive technologies; introducing–

CPB platform

Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), to successfully discover & guide the development of novel life-science based products.

Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders & internal results

CPB – Computational Predictive Biology



Tailor-made **Engines** for product discovery & development

The CPB platform enhances product discovery and development through dedicated **Engines** for products based on three core components:

- Microbes
- Small molecules
- Genetic elements



Tailor-made **Engines** for product development

Discovery

Computational selection of the most promising candidates to initiate the product development process.

Development

Computational driven solution addressing optimization development challenges for the selected candidates, without impairing their ability to address other product attributes, supporting the way to successful commercialization.



Business Model



1

Product development through collaborations

Joint development with leading companies for defined products utilizing Evogene's unique solution. Later-stage development and commercialization of the product will likely be done by the partner.

Potential revenue for Evogene

- Licensing and research payments
- Milestone payments
- Revenue sharing

Main Business Model Until 2014:

BAYER

- GMO seed traits for yield and abiotic stress for wheat

DUPONT

- GMO seed traits for yield and abiotic stress for corn
- GMO seed traits for ASR resistance for soybean

MONSANTO

- GMO seed traits for yield and abiotic stress for corn and soybean
- GMO (2013) and genome editing (2019) seed traits for fusarium resistance

syngenta

- GMO seed traits for nematode resistance

Business Model



2

Product development through subsidiaries

Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene's unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations.

Potential revenue for Evogene

- Licensing and research payments
- Consolidated revenues
- Dividends (subject to profits generated by subsidiary)

Main Business Model from 2015:

agPlenus
Ag-chemicals

BIOMICA
Microbiome based therapeutics

CANONIC
Medical cannabis

casterra
Ag-solutions for castor

lavie bio
Ag-biologicals

Agenda

- Introduction
- **Fields of activity**
- Main subsidiaries
- Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals



Potential fields of activity



Current life-science based products under development



		HUMAN HEALTH	AGRICULTURE	OTHER INDUSTRIES
MicroBoost AI	MICROBES	Microbiome based Therapeutics	Ag-Biologicals	
ChemPass AI	SMALL MOLECULES	Drugs based on small molecules	Ag-Chemicals	
GeneRator AI	GENETIC ELEMENTS	Medical Cannabis	Seed Traits	Ag-solutions for castor oil production

CPB

Development & commercialization through subsidiaries and collaborations

	HUMAN HEALTH	AGRICULTURE	OTHER INDUSTRIES
MICROBES — MicroBoost AI	BIOMICA	lavie bio	
SMALL MOLECULES — ChemPass AI	BIOMICA*	agPlenus	
GENETIC ELEMENTS — GeneRator AI	CANONIC	Seed Traits [division]	casterra

CPB

* non-exclusive license

Evogene Group – More to Come

New activity

We are now evaluating the initiation of discovery and development of new life-science based products in various new fields of activity.

	HUMAN HEALTH	AGRICULTURE	OTHER INDUSTRIES
MicroBoost AI – MICROBES		Microbe for aquaculture*	
ChemPass AI – SMALL MOLECULES	Drug optimization*		
GeneRator AI – GENETIC ELEMENTS		High quality food by genome editing*	

* under evaluation

Evogene Group

Human Health

BIOMICA

90%*

Microbiome based Therapeutics

- Immuno-oncology
- GI- gastrointestinal-related disorders
- MDRO – multi-drug resistant organisms

CANONIC

100%*

Medical Cannabis

- High yield & consumer traits
- Therapeutic traits – currently inflammation & pain

Agriculture

agPlenus

98%*

Ag Chemicals

- Herbicides
- Insecticides
- Fungicides

lavie bio

72%*

Ag Biologicals

- Bio-Stimulants
- Bio-Pesticides

Internal division of Evogene

Seed Traits

- Yield improvement and drought tolerance
- Plant disease
- Insect control

Other Industries

casterra

100%*

Castor Oil Production

- Castor seeds & growth protocol

*Evogene holdings

Agenda

- Introduction
- Fields of activity
- **Main subsidiaries**
- Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals



BIOMICA | Human Microbiome

Mission:
Discovery and development of novel therapies for microbiome-related human disorders using computational biology.

MicroBoost AI ChemPass AI

Product Pipeline:

Immuno-oncology program:
- Combination therapy for cancer with checkpoint inhibitors
- Pre-clinical stage
- Addressable market size expected by 2026* – $243B

GI related disorders:
- Inflammatory Bowel Disorder (IBD) – pre-clinical stage
- Irritable Bowel Syndrome (IBS) – discovery stage
- Addressable market size expected by 2026: Inflammatory Bowel Disorder $22.4B, Irritable Bowel Syndrome** $3.3B

MDRO:
- Multi Drug Resistant Organisms (antimicrobial resistance)
- Clostridium Difficile Infection (CDI) – discovery stage
- Methicillin-resistant Staphylococcus aureus (MRSA)– discovery stage
- Addressable market size expected by 2026: CDI*** $1.7B, MRSA**** $3.9B

Expected main near-term value drivers:

2021
- **IBD** - extend pre-clinical study
- **Immuno-oncology** - initiate proof of concept, first in human study

2022
- **IBD** - initiate first GMP production of drug candidates for IBD
- **Immuno-oncology** - readout from proof of concept, first in human study

*https://www.globenewswire.com/news-release/2019/07/17/1884118/0/en/Cancer-Immunotherapy-Market-To-Reach-USD-242-86-Billion-By-2026-Reports-And-Data.html
**https://www.bloomberg.com/press-releases/2019-07-23/ibs-treatment-market-size-worth-3-3-billion-by-2026-cagr-10-1-grand-view-research-inc
***www.globaldata.com/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/
****www.prnewswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-39-billion-by-2025-upsurge-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html

Example Results:

Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo



Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program

Biomica's, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year

Rehovot, Israel – September 8, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced positive pre-clinical in-vivo results in its immuno-oncology program for a follow-on combination of bacterial strains. In these studies, Biomica tested BMC128, which consists of four live bacterial strains derived from Biomica's drug candidates BMC121 and BMC127. Treatment with BMC128, both prior to and in combination with ICI, significantly improved anti-tumor activity in mice.

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma

Biomica's live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

Rehovot, Israel – April 13, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced additional positive pre-clinical results in its immuno-oncology program demonstrating efficacy of its live biotherapeutic product (LBP) consortium BMC128, this time in melanoma. In these studies, Biomica tested BMC128, which consists of four live bacterial strains, in a mouse model of melanoma.

CANONIC | Medical Cannabis

Mission:
Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology.

GeneRator AI

Product Pipeline:

MetaYield Products:

- Stable enhancement of total plant compounds:
  - Increased compounds per plant
  - Increased compounds per area
- Total Cannabis market size expected by 2024 – $42.7B*

Precise Products:

- Stable enhancement of specific active compounds for pain and inflammation:
  - Medical indication focus
  - Compound profile focus
- Medical Cannabis market size expected by 2024 – $25.6B*

*Source: Arcview Market research/BDS Analytics 2020

Expected main near-term value drivers:

2021

- **MetaYield** - reach 1st commercial variety; sign production and distribution agreements in anticipation for commercialization in 2022
- **Precise** - identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation

2022

- **MetaYield** - commercial launch and initial sales of first product in Israel
- **Precise** - reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023

CANONIC | Medical Cannabis

Example Results:

MetaYield products under development – increased compounds per area, addressing the T20/C4 (THC 16%-24% and CBD 0%-7%) market segment, which currently consists of 70% of the Israeli medical cannabis market

Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes

Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products

Collaboration to combine the cannabis expertise of both parties, including extensive clinical and related data of Cannbit and leading computational predictive biology capabilities and genomic data of Canonic

Tel-Aviv and Rehovot, Israel – February 24th, 2021 – Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. (TASE: TKUN), a leading medical cannabis company, and Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis products, today announced that they have entered into a collaboration agreement for the development of novel medical cannabis products.

Canonic of Evogene Group and Tikun Olam (Israel)-Cannbit, sign production and distribution agreements for Canonic products in Israel

Rehovot and Tel-Aviv, Israel – March 25th, 2021 – Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis products and Tikun Olam-Cannbit Pharmaceuticals Ltd. (TASE: TKUN), a leading medical cannabis company, today announced that they have entered into agreements for the production and distribution in Israel of Canonic's medical cannabis products. Canonic's first product is expected to be launched in Israel next year.

agPlenus | Ag-Chemicals

Mission:
Design of next-generation effective, sustainable and safer crop protection products by leveraging computational biology and chemistry.

ChemPass AI

Product Pipeline:

Herbicides:

- Novel MoA (Mode-of-Action) selective/non-selective herbicides
- Relevant target crops – Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBD
- Addressable market size expected by 2022*: $34B
- Lead stage

Insecticides:

- Novel SoA (Site-of-Action)
- Addressable market size expected by 2022*: $19B
- Hit-to-Lead stage

*https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-2022---research-and-markets-300458389.html

Expected main near-term value drivers:

2021

- **New MoA Herbicide** - reach a herbicide tolerance trait POC for a 'Lead' herbicide under development
- **New MoA Herbicide/SoA Insecticide -** sign a licensing agreement for a leading candidate

2022

- **New MoA Herbicide** - sign a strategic agreement for the development of an 'Optimized Lead' compound
- **New MoA Herbicide** - reach an 'Optimized Lead' phase in the herbicide program

agPlenus | Ag-Chemicals

Example Results:

Leading novel MoA herbicide candidate – displaying efficacy in eradicating multiple important weed species in field tests



Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

This significant development milestone was achieved following positive results for product candidate APH1 in field tests with commercial level application rates on a broad panel of weeds

Rehovot, Israel – December 15, 2020 – AgPlenus Ltd., an innovative company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), announced today that it has reached the 'Lead' stage in its novel Mode-of-Action (MoA) herbicide program. The achievement of this milestone follows the conclusion of field tests that demonstrated that product candidate APH1, at commercial dose rates, effectively controlled a broad panel of weeds, including weeds that are known to have resistance to existing herbicides. These results were confirmed in independent field tests conducted by SynTech Research, an agricultural R&D contract research organization located in California.

lavie bio | Ag-Biologicals

Mission:
Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology.

MicroBoost AI

Product Pipeline:

Bio-stimulants (live microbials for yield improvement):

- Spring wheat – seed treatment/soil application – development stage 2
- Corn – seed treatment – pre-development stage
- Addressable market size*: corn – 120M acres, spring wheat – 25M acres

Bio-pesticides (live microbials for pest protection):

- Mildew, fruit rot for fruit and vegetables (initial focus on grapes) – foliar application – development stage 1
- Seedling disease for corn, soy – seed treatment for disease protection – pre-development stage
- Bio-insecticides – initial focus corn (seed treatment), soy (foliar) – pre-development stage
- Addressable market size*: mildew, fruit rot – $550M, seedling diseases – $500M, bio-insecticides – $1.5B.

*Company estimation

Expected main near-term value drivers:

2021

- **Fruit rot bio-fungicide** – product advancement of LAV311 or 312 development towards regulation
- **Bio-stimulant** - conduct pre-commercial trials for LAV211 in spring wheat

2022

- **Bio-stimulant** - initial product sales of LAV211 for spring wheat
- **Fruit rot bio-fungicide** - file for regulatory approval for leading product candidate LAV311 or LAV312

lavie bio | Ag-Biologicals

Example of treatment with LAV312 against Botrytis Cinerea in vines – untreated control vs treated vines

Lavie Bio's wheat field in the USA during harvest

Lavie Bio Announces Positive Results for LAV311 and LAV312 in its Bio-Fungicide Program

Positive results were achieved in a series of vineyard trials for bunch rot diseases conducted in Europe and the United States

Rehovot, Israel – October 29, 2020 – Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today positive trial results for two of its leading bio-fungicide product candidates. The successful results for LAV311 and LAV312, targeting bunch rot diseases, mark the advancement of these candidates to "Development Stage 2" **[1]** These vineyard trials, conducted in target locations in Europe and the U.S., resulted in significantly better efficacy and consistency than existing comparable commercial biological benchmarks, and competitive to commercial chemical benchmarks, both tested as part of these trials. The positive results will support Lavie Bio's current plan to launch its first bio-fungicide product for controlling bunch rots for use in fruit and vegetables in 2024.

Lavie Bio Provides Product Pipeline Update for 2020

LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs

Rehovot, Israel – December 29, 2020 – Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022.

Subsidiaries - expected main near-term value drivers

	2021		2022	
BIOMICA	**Inflammatory Bowel Disease (IBD)** - extend pre-clinical study	**Immuno-oncology** - initiate proof of concept, first in human study	**IBD** - initiate first GMP production of drug candidates for IBD	**Immuno-oncology** - readout from proof of concept, first in human study
CANONIC	**MetaYield** - reach 1st commercial variety; sign production and distribution agreements in anticipation for commercialization in 2022	**Precise** - identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation	**MetaYield** - commercial launch and initial sales of first product in Israel	**Precise** - reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023
agPlenus	**New MoA Herbicide** - reach a herbicide tolerance trait POC for a 'Lead' herbicide under development	**New MoA Herbicide/SoA Insecticide** - sign a licensing agreement for a leading candidate	**New MoA Herbicide** - sign a strategic agreement for the development of an 'Optimized Lead' compound	**New MoA Herbicide** - reach an 'Optimized Lead' phase in the herbicide program
lavie bio	**Fruit rot bio -fungicide** – product advancement of LAV311 or 312 development towards regulation	**Bio-stimulant** - conduct pre-commercial trials for LAV211 in spring wheat	**Bio-stimulant** - initial product sales of LAV211 for spring wheat	**Bunch rot bio-fungicide** - file for regulatory approval for leading product candidate LAV311 or LAV312

Pipeline Regulation Collaboration Product Launch

Agenda

- Introduction
- Fields of activity
- Main subsidiaries
- **Summary**

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals



Summary

Our vision - Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and artificial intelligence technologies

The CPB's three unique engines target to improve the development of products based on the following core components:

1. MicroBoost AI – for products based on microbes
2. ChemPass AI – for products based on small molecules
3. GeneRator AI – for products based on genetic elements

Dual based business model - utilizing Evogene's solutions for:

1. Product development & commercialization through collaborations
2. Product development & commercialization through subsidiaries

Four main market-oriented subsidiaries, each with a clear milestone roadmap:

1. Biomica – human-microbiome based therapeutics
2. Canonic – medical cannabis
3. AgPlenus – ag-chemicals
4. Lavie Bio – ag-biologicals

Significant catalysts expected in the next 12 months towards 2022 product commercialization & strategic collaborations


THANK YOU!
evogene
DECODING BIOLOGY



Annex I:
Addressing the discovery and development challenges of life science-based product

The **challenge** in creating life-science based products

The **challenge** in creating life-science based products

Common practice

Discovery – selection of product candidates mainly addressing efficacy

Product Definition → **Candidate Selection** | Efficacy | Safety | Selectivity | Shelf-life | Other | **Product Launch**

The **challenge** in creating life-science based products

Common practice

Discovery – selection of product candidates mainly addressing efficacy

Development – inefficient optimization & difficulty in addressing a single challenge without impairing others

X Low probability of success

X Long time to market

X High development costs

Evogene's AI-based solution: Discovery

A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI.

Evogene's AI-based solution: Development

A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.

Evogene's AI engines provide tailor-made solutions

Discovery

Computational prediction of candidates, to serve as the **product's core-component**, addressing multiple key product attributes.

Development

Computational driven solution for guiding and assessing the optimization process of the **selected core component**, without impairing other key product attributes.

MicroBoost AI

ChemPass AI

GeneRator AI

Annex II:
Financial Fundamentals

Key Financials: Balance Sheet

Thousands of US $	31.12.2020	31.12.2019
Current Assets	51,823	49,027
Long-Term Assets	20,092	22,337
Total Assets	**71,915**	**71,364**
Current Liabilities	9,676	5,746
Long-Term Liabilities	5,357	5,401
Equity attributable to equity holders of the Company	46,045	50,144
Non-controlling interest	10,837	10,073
Total Liabilities & Shareholders Equity	**71,915**	**71,364**

Key Points:

- Consolidated cash position: ~$48.2 million as of 31.12.2020, ~$13 million appropriated to Lavie Bio
- No bank debt
- Estimated net cash usage for 2021, excluding Lavie Bio: $20-$22 million
- Listed on TASE (2007) and NASDAQ (2016)

Exhibit 99.2

Forward-Looking Statements

This presentation contains "forward-looking statements" relating to future events, and AgPlenus (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Agenda

- Company introduction
- Business model
- Product pipeline
- Technology
- Milestone roadmap

OUR VISION

We design next-generation, effective, sustainable and safer crop protection products by leveraging predictive biology & chemistry

Growing market for Crop Protection products with need for innovation

Growing market



Source: Facts & Factors

Product introductions lag



Source: Phillips McDougall Database

No new Mode-of-Action (MoAs) for 3 decades
Major Ag companies have failed to meet the demand for innovation

Herbicide resistant weeds have flourished

- Overuse of existing Modes of Actions (MoAs) has generated selection pressure
  - 263 herbicide-resistant weed species have evolved*
- Substantial economic cost to farmers
  - Increase costs and reduce yields
  - United States:
    - Soybeans: $35/acre additional costs**
    - $2 billion / year increased costs and lost yields***

Sources * Intl. Herbicide Resistant Weed Database
** AgriBusiness Global, Farm Progress
*** Michigan Farm News

AgPlenus' target-based technology addresses the challenges



Discovery
Computational selection of the **most promising candidates** to initiate the product development process

Optimization
Computationally driven solution addressing **optimization development** challenges for the selected candidates, supporting the way to successful commercialization.

AgPlenus' Technology

Powered by:

evogene | ChemPass AI

Experienced board of directors

Ofer Haviv
Chairman of the board

- Evogene, President & CEO

Robert A. Woods

- Marrone Bio Innovations, Inc., Chairman
- Bioenterprise capital private equity
- Previously, Syngenta, President USA

Eli Assraf

- Galam Ltd., Director
- Previously, Makhteshim Agan (Adama), CFO & COO
- Strauss Group, CFO

Eran Kosover

- Previously AgPlenus Ltd., CEO
- Evogene EVP & GM Crop Protection, Evogene VP of collaborations,
- Atera Networks

Innovative & experienced management team

Douglas A. Eisner
CEO

Previous positions:

- AgroSpheres, Inc., CEO
- GrassRoots Biotechnology, Inc., Co-founder and COO

Boaz Inbal
VP R&D

Previous positions:

- Epix pharmaceuticals, Director
- Insilicore, CEO
- Promining therapeutics, CTO

Mirit Ram
Director of Project Management

Previous positions:

- Evogene, PM
- FMC, PM
- HP

Agenda

- Company introduction
- Business model
- Product pipeline
- Technology
- Milestone roadmap

Product development stages



Business model – value creation through product development process

As candidates move further through our pipeline,
we expect to receive higher fees from collaborators and licensees.



Crop protection industry

- Dominated by four Major ag-chemical companies

  - 70%* of ag-chemical crop protection market
  - Pace of innovation and new product introductions have slowed

- Looking to smaller, ag-tech companies to develop new small-molecule candidates
  - AgPlenus is leading the integration of computational technology to discover small molecules
  - Focusing on developing products with new MoAs

* Canadian Council on Food Safety and Health

Business model & potential revenue stream



License fees & R&D fees

- We typically provide our collaborators **exclusive licenses** with respect to a specified discovery, product type or market area
- **Research & development fees** typically cover the costs we incur during the discovery and optimization activity

Milestone payments

- When our product candidates reach **significant development milestones** in the product development pipelines of our collaborators

Royalties

- Royalty payments from **sales of commercial products** developed under the collaboration

Corteva collaboration

- Develop new MoA herbicides to target resistant weeds
  - Entered March 2020
  - AgPlenus will discover and optimize herbicide candidates
  - Corteva will conduct testing and product development

- License to Corteva
  - Corteva has exclusive license to products of collaboration
  - AgPlenus receives research fees, milestones and royalties upon commercialization

- Goal for 2021
  - Advance development of collaboration compounds

Agenda

- Company introduction
- Business model
- Product pipeline
- Technology
- Milestone roadmap

Products under development

Herbicides:

- Novel MoA (Mode-of-Action) herbicides
- Optimize existing herbicides to overcome resistance
- High value crops – Corn, Soybean, Cereals, Rice, Cotton, Canola …
- By 2022, addressable market expected: $34B

Insecticides:

- Novel SoA (Site-of-Action)
- By 2022, addressable market expected : $19B

Sources: Research and Markets, Markets and Markets

AgPlenus product pipeline



APH 1 – New MoA herbicide reached Lead stage

- Broad-spectrum weed control at commercial dosage rates
- Effective against resistant weed strains – including *Palmer Amaranth*



(16DAA) (Rehovot, Israel; Aug. 2020)

APH 1 - a new MoA non-selective herbicide candidate

Product Efficacy	• APH 1 displays herbicidal activity on multiple important weed species, both grasses and broad-leaves
New MoA	• APH 1 active on a new MoA – providing a solution to the rising resistance problem
Market Potential	• Relevant target crops – Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar beet • Leading relevant geographies
Safety	• APH 1 target/MoA does not exist in human – high safety potential • Molecule safety predicted using multiple computational tools
Production	• Molecule and several analogs synthesized • Ongoing efforts to reduce production costs
Product Application	• Good solubility, APH 1 active in water-based formulations • APH 1 active both in pre- and post-emergence applications



New MoA Herbicide active at commercial concentrations



APH 1 – Product efficacy

Product Efficacy

- APH 1 displays herbicidal activity on multiple important weed species, both grasses and broad-leaves



- Strong activity on a broad panel of target weeds
- No weed recovery from herbicide effect

LTP single dose (0.75 kg/ha), pre, TP2 (18DAA)



- Strong activity in pre-application on both grasses and broad leaves

Broad activity, pre and post application

APH 1 is a new MoA non-selective herbicide candidate
Key next milestones



Agenda

- Company introduction
- Business model
- Product pipeline
- Technology
- Milestone roadmap

AgPlenus technology empowered by Evogene's ChemPass AI



Computational prediction of multiple product attributes



* In-process / Planned

From target to an optimized lead



Experimental pipeline up to ‘Lead’ stage












Agenda

- Company introduction
- Business model
- Product pipeline
- Technology
- Milestone roadmap

Expected main near-term value drivers

2021

- **New MoA Herbicide** – reach a herbicide tolerance trait POC for a 'Lead' herbicide under development
- **New MoA Herbicide/SoA Insecticide** - sign a licensing agreement for a leading candidate

2022

- **New MoA Herbicide** – reach an 'Optimized Lead' phase in the herbicide program
- **New MoA Herbicide** – sign a strategic agreement for the development of an 'Optimized Lead' compound

We are AgPlenus

Creating effective, sustainable and safer crop protection products


agPlenus
THANK YOU

Exhibit 99.3

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Biomica Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Founded Israel, 2017

Subsidiary of Evogene Ltd.
(NASDAQ, TASE: EVGN)

A pioneer in the field of applied computational predictive biology

Holds Approx. 90%

HIGHLIGHTS

Mission
Developing innovative microbiome-based therapeutics

Emerging biopharmaceutical company

Focus
Treatment of immune-mediated and infectious diseases:

- Immuno-Oncology
- Gastrointestinal (GI) related disorders
- Antimicrobial resistance (AMR)

Pipeline
Enabled by a unique computational predictive biology platform (combining 'Big-Data' & Artificial Intelligence technologies)


The Microbiome and its Functions
The human gastrointestinal tract comprises approximately 10^{14} microbes and amounts to a biomass of approximately 2kg!
Trillions of microbes living in & on our bodies, acting as a "**Other Genome**"
For every human gene there are 100 microbial genes
Microbes play a **critical role** in food digestion, protection from diseases and production of nutrients
Clinical evidence is accumulating for microbiome's role in a wide array of illnesses
Solving dysbiosis, a state of microbial imbalance in the body, is at the **core of new therapeutic approaches**

Market Landscape

Rapid growing industry

2024

70%
CAGR

Multi $Bn
market opportunity

> $4Bn
invested in microbiome companies since 2014

A record
in Microbiome investment levels are set in 2017 & 2018, and growing

2018

Key Drivers

Big Pharma

Johnson & Johnson · MERCK · Roche · FERRING PHARMACEUTICALS · Takeda · Nestlé HealthScience

Prominent VCs

OrbiMed · Seventure · FLAGSHIP PIONEERING

Active companies

SECOND GENOME · SERES THERAPEUTICS · EVELO · VEDANTA BIOSCIENCES

Current areas of focus



Most candidates are still in the discovery & preclinical stages; few are in clinical stage (Ph. II/III)

Sources:
BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics Market SVB – Emerging Healthcare: Microbiome Investment Trends Aug 2017)
https://www.microbiometimes.com/the-microbiome-biotech-landscape-an-analysis-of-the-pharmaceutical-pipeline/

Biomica's Mission and Focus

Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology

The Challenge

Microbiome space is Big-Data driven

Multi-OMICS big-data & clinical meta-data needed for addressing specific biological questions

How to cope with enormous amount of information?

The common practice:
The biological (trial and error) approach

It has 2 disadvantages:

A needle in a haystack...

Guessing the lottery numbers

The Competitive Edge

Our computational technologies enable data integration, analysis & prediction

CPB platform

Databases generated via data integration capabilities

+

Proprietary computational algorithms (AI) utilized to mine data

Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders & internal results



BIOMICA

CPB – Computational Predictive Biology

Scientific Approach



PRISM - Platform Capabilities

PRISM
Microbiome target discovery

FunctionFinder
Comprehensive digital representation of microbiome **function**

StrainIdentifier
Accurate digital representation of microbiome **strains**

Strain-Function allocator

Comparative analysis tools

Clinical Data

Consolidator

Human Genomics

Biomica's Edge

Our computational platform is capable of **unprecedented high-resolution** microbiome analysis

Pioneers in the field of **functional microbiome analysis,** leading innovative technology

Minimum Microbial Strains

Maximum Relevant Functions

Maximal Therapeutic Impact

Advantages of our approach Vs. others in the field:

- Fecal Microbiota Transplant (FMT): Collection of 10,000s entities, no QC
- Single-strain method: We bring higher efficiency due to multiple MoAs
- Other multi-strain rationally-designed LBPs: We optimize a consortium for better efficacy with less adverse effects (due to fewer & carefully selected entities)

Biomica's Discovery Pipeline

	Program	Indication / Target	Discovery	Preclinical	Phase 1	Phase 2	Approach
Immuno-oncology (with ICI*)	BMC121	Combination Therapy for NSCLC**					
	BMC127	Combination Therapy for NSCLC					
	BMC128	Combination Therapy for NSCLC					
GI related disorders	BMC321	IBD					
	BMC322	IBD					
	BMC426	IBS					
Antimicrobial resistance (**AMR*****)	BMC202	C. difficile toxin-B					

In the AMR Program, Biomica has a collaboration with Nobel Prize Laureate Prof. Ada Yonath at Weizmann Institute of Science to develop a selective treatment for MRSA

Live Biotherapeutics

Small-molecule

*Immune Checkpoint Inhibitors, ** Non-small-cell lung carcinoma (NSCLC), ***Previously this program was referred to as "Multi-drug resistant organisms"

Response to Immunotherapy is Modulated Through Specific Bacterial Functions



BIOMICA

*Based on Biomica's computational analysis

Fecal Microbiota Transplantation (FMT) and re-Induction of anti-PD-1 Therapy in Refractory Patients - POC



"...Now, another potential therapy is being tested in clinical studies: fecal transplants. Early results from two groups described at the annual meeting of the American Association for Cancer Research (AACR) here this week suggest some patients who initially did not benefit from immunotherapy drugs saw their tumors stop growing or even shrink after receiving a stool sample from patients for whom the drugs worked..."

"...One unresolved question is exactly which microbes help ramp up the desired immune activity..."

https://www.sciencemag.org/news/2019/04/fecal-transplants-could-help-patients-cancer-immunotherapy-drugs

Modulating gut microbiota to treat cancer

Science

REPORTS

Cite as: E. N. Baruch *et al.*, *Science* 10.1126/science.abb5920 (2020).

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Erez N. Baruch[1,2*†], Ilan Youngster[3,4], Guy Ben-Betzalel[1], Rona Ortenberg[1], Adi Lahat[5], Lior Katz[6], Katerina Adler[7], Daniela Dick-Necula[8], Stephen Raskin[4,9], Naamah Bloch[10], Daniil Rotin[8], Liat Anafi[8], Camila Avivi[8], Jenny Melnichenko[1], Yael Steinberg-Silman[1], Ronac Mamtani[11], Hagit Harati[1], Nethanel Asher[1], Ronnie Shapira-Frommer[1], Tal Brosh-Nissimov[12], Yael Eshet[4,8,13], Shira Ben-Simon[10], Oren Ziv[10], Md Abdul Wadud Khan[14], Moran Amit[15], Nadim J. Ajami[14], Iris Barshack[4,8], Jacob Schachter[1,4], Jennifer A. Wargo[14,16], Omry Koren[10], Gal Markel[1,2,17*‡], Ben Boursi[4,18,19‡]

CLINICAL TRIALS

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Diwakar Davar[1*], Amiran K. Dzutsev[2*], John A. McCulloch[2], Richard R. Rodrigues[2,3], Joe-Marc Chauvin[1], Robert M. Morrison[1], Richelle N. Deblasio[1], Carmine Menna[1], Quanquan Ding[1], Ornella Pagliano[1], Bochra Zidi[1], Shuowen Zhang[1†], Jonathan H. Badger[2], Marie Vetizou[2], Alicia M. Cole[2], Miriam R. Fernandes[2], Stephanie Prescott[2], Raquel G. F. Costa[2], Ascharya K. Balaji[2], Andrey Morgun[4], Ivan Vujkovic-Cvijin[5], Hong Wang[6], Amir A. Borhani[7], Marc B. Schwartz[8], Howard M. Dubner[8], Scarlett J. Ernst[1], Amy Rose[1], Yana G. Najjar[1], Yasmine Belkaid[5], John M. Kirkwood[1], Giorgio Trinchieri[2‡§], Hassane M. Zarour[1,9‡§]

Anti–programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut microbiota correlates with anti–PD-1 efficacy in preclinical models and cancer patients. To investigate whether resistance to anti–PD-1 can be overcome by changing the gut microbiota, this clinical trial evaluated the safety and efficacy of responder-derived fecal microbiota transplantation (FMT) together with anti–PD-1 in patients with PD-1–refractory melanoma. This combination was well tolerated, provided clinical benefit in 6 of 15 patients, and induced rapid and durable microbiota perturbation. Responders exhibited increased abundance of taxa that were previously shown to be associated with response to anti–PD-1, increased $CD8^+$ T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells. Responders had distinct proteomic and metabolomic signatures, and transkingdom network analyses confirmed that the gut microbiome regulated these changes. Collectively, our findings show that FMT and anti–PD-1 changed the gut microbiome and reprogrammed the tumor microenvironment to overcome resistance to anti–PD-1 in a subset of PD-1 advanced melanoma.

Davar *et al.*, *Science* **371**, 595–602 (2021) 5 February 2021

1 Cancer Immunotherapy - Combination Therapy
Initial Focus on Lung Cancer (NSCLC)

- Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide
- Current solutions reach only an average of **17%-20%*** overall response rate

Biomica aims to improve clinical response of ICI through immunomodulating combination therapy

BMC121 & BMC127

Rationally designed consortia aimed to facilitate anti-tumor activity in combination with ICI

- Orally administered capsule, comprised of 4 bacterial strains each, detected through Biomica's proprietary computational functional genomic analysis platform
- Strains were selected based on specific functional capabilities and their immuno-stimulatory potential
- The combination of 4 different microbial strains in a consortium is aimed to achieve effective immune activation through several underlying and complementary mechanisms



* American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018.

BMC121 & BMC127 potentiate the effect of anti-PD1 therapy *in vivo*

Mean Tumor Volume and Time To Endpoint significantly improved







Optimizing our IO consortia: BMC128





A new combination providing all microbial functions & presenting higher likelihood for survival in GI.

BMC128

BMC128 administered prior to and in combination with anti-PD1 significantly improved anti-tumor activity



Sep 8th, 2020

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program

Biomica's, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year

Rehovot, Israel – September 8, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced positive pre-clinical in-vivo results in its immuno-oncology program for a follow-on combination of bacterial strains. In these studies, Biomica tested BMC128, which consists of four live bacterial strains derived from Biomica's drug candidates BMC121 and BMC127. Treatment with BMC128, both prior to and in combination with ICI, significantly improved anti-tumor activity in mice.

ORR (CR+PR):
23.5% vs 34.8%
48% increase in responders

The study indicates that pre-treatment with BMC128 conditions the immune system and primes it for an efficient anti-tumor response

*BMC 128 - Consist of 4 live bacterial strains derived from BMC121 and BMC127

BMC128 Demonstrating Efficacy of in Melanoma

BMC128 significantly enhanced anti-tumor activity, resulting in an increased response of melanoma tumors to anti-PD1



Apr 13th, 2021

CISION PR Newswire

News | Products | Contact

News in Focus | Business & Money | Science & Tech | Lifestyle & Health | Policy & Public Interest | People & Culture

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma

USA - English

Biomica's live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

NEWS PROVIDED BY
Biomica →
Apr 13, 2021, 07:00 ET

SHARE THIS ARTICLE

These results demonstrate the potential applicability of BMC128 and its relevance to **treating multiple types of solid tumors**

First-in-human, proof of concept study expected to initiate later this year

- BMC128 consists of **4 live bacterial strains**
- Results demonstrated a significant **reduction of tumor volume**, and **increased animal survival** compared to anti-PD1 therapy alone
- **MOA is immune mediated**- increased tumor inflammation & infiltration of T lymphocytes and NK cells
- Potential applicability in the treatment **various types of solid tumors**


CISION
PR Newswire
News Products Contact
Oct 13th, 2020
News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest People & Culture
Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program
English
The company is advancing to scale-up and GMP batch production, to support anticipated first-in-man proof-of-concept clinical trials next year
BIOMICA
NEWS PROVIDED BY
Biomica
Oct 13, 2020, 07:00 ET
SHARE THIS ARTICLE

Predictor of Patients' Response to ICI

Utilizing AI and PRISM-generated high-res microbiome profiles



2 GI Related Disorders
IBS & IBD

Irritable Bowel Syndrome (IBS)*

A common intestinal functional disorder, group of symptoms:

- Abdominal Pain
- Constipation or Diarrhea
- Bloating, Gas & Diarrhea

In collaboration with The University of North Carolina (UNC) at Chapel Hill

Inflammatory Bowel Disease (IBD)**

A group of inflammatory conditions of the colon and small intestine (Crohn's disease, Ulcerative colitis & Pouchitis)

Approximate number of patients: 43M



Approximate market size (USD)



Both clearly related to the microbiome

Biomica pushes the barriers posed by existing therapies by addressing the underlying cause of the disorder, rather than the symptoms

*https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market
**https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026

Established Role for Microbiome in IBD Etiology

A state of inflammation is associated with reduced richness of microbial taxa and functions



Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches

R. Balfour Sartor[1,*] and Gary D. Wu[2,*]
[1]Departments of Medicine, Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
[2]Division of Gastroenterology, Perelman School of Medicine, the University of Pennsylvania, Philadelphia, PA 19104

Gastroenterology. 2017 February

Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches

Jonathan J. Hansen, M.D., Ph.D.[1] and **R. Balfour Sartor, M.D.**[2]
Jonathan J. Hansen: jjhansen@med.unc.edu; R. Balfour Sartor: rbs@med.unc.edu

Curr Treat Options Gastroenterol. 2015 March

BMC321 & BMC322

Rationally designed consortia aimed to reduce inflammation for the treatment of IBD

- Orally administered capsule, comprised of 4 bacterial strains each, detected through Biomica's proprietary computational functional genomic analysis platform
- Strains were selected based on their anti-inflammatory functions targeting both immunocytes and intestinal mucosal cells
- The combination of 4 different microbial strains in a consortium is aimed to effectively attenuate inflammation through several complementary mechanisms
- Support growth and metabolism of other consortium members and the growth of additional favorable gut resident bacteria

		Microbial component / function						Host response								Interactions with other microorganisms	
Consortium	Microorganism	SCFA	Function 61458	Function 314622	Function 314623	Function 32072	Function 2456	Tregs ↑	mechanism1	mechanism2	mechanism3	mechanism4	mechanism5	mechanism6	mechanism7	with other members in consortium	with other gut residents
BMC321	BMCS311	■		■				■	■	■	■	■	■	■	■	■	
	BMCS315	■					■	■	■		■	■		■	■		■
	BMCS313	■			■	■		■	■		■	■		■	■	■	■
	BMCS318		■					■	■							■	■

Currently undergoing pre-clinical studies

BMC321 & BMC322 indicate to reduce inflammation in a DSS-treated mouse model*

Gut Inflammation level, During DSS treatment







Severe inflammation (% of total number of mice):
Control - 43% VS. BMC322- 10%

*Preliminary results

3 C. difficile Infection (CDI) - Landscape



Gram-positive, anaerobic, spore-forming, toxin-producing bacillus

Most common hospital-acquired infections (Over 600,000 a year)

Increasing cause of morbidity and mortality (older hospitalized patients)

Incidence & associated mortality progressively increasing in W.countries

15%–25% of all cases of antibiotic-associated diarrhea result from CDI

- **Pathogenicity of C. difficile is mainly mediated by two exotoxins**
- Infection manifestations:
  - Diarrhea
  - Abdominal cramping and pain
  - Fever
  - Nausea
- **The economic cost of CDI est. as $5.4Bn mostly due to hospitalization**

BMC202

- Our approach is to utilize **BMC202** as a non-antibiotic inhibitor of C. difficile toxin, which is responsible for the symptoms associated with CDI, **while preserving healthy gut microbiome**
- BMC202 is a selective anti-bacterial agent designed to inhibit the glucosyl-transferase domain of the C. difficile toxin (TcdB)
- The drug candidate has been identified using Biomica's in silico chemical screening platform, which enables high throughput screening of a database of **~300M** molecules.

Desai et al. BMC Infectious Diseases (2016) 16:303; Toxins 2016, 8, 134

A collaboration between Biomica and the Weizmann Institute of Science



[The company has in-licensed IP and knowhow generated by the Nobel Prize Laureate Prof. Ada Yonath, who supports Biomica's work on this program]

Biomica develops a **selective** treatment against antibiotic resistant strains of Staphylococcus aureus (MRSA) infection, in a microbiome focused approach utilizing proprietary computational tools

- MRSA is a multi-drug resistant bacterium, responsible for several difficult-to-treat infections, leading to tens of thousands of annual cases of mortality in the US
- MRSA market in 2016 was approximately $2.9Bn, projected to reach over $3.9Bn by 2025*.

*https://www.prnewswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-39-billion-by-2025-upsurge-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html

nature reviews drug discovery

NEWS · 11 SEPTEMBER 2020

First microbiome-based drug clears phase III, in clinical trial turnaround

Seres Therapeutics' stool-derived treatment for recurrent *Clostridium difficile* infection could become the first FDA-approved microbiome therapy. Several other live biotherapeutic microbial products are close behind.

Ken Garber

BOSTON BUSINESS JOURNAL

Health Care

GREATER BOSTON SMALL BUSINESS RESOURCE GUIDE

Local, state and federal resources to help your business ›

Seres stock jumps 400% on microbiome trial success

businesswire

A BERKSHIRE HATHAWAY COMPANY

HOME SERVICES NEWS EDUCATION ABOUT US

Search

Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

businesswire

A BERKSHIRE HATHAWAY COMPANY

HOME SERVICES NEWS EDUCATION ABOUT US

Search

Rebiotix and Ferring Announce World's First With Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660

The recent positive Phase 3 clinical data provide strong validation for the utilization of microbiome therapeutics and helps validate Biomica's science and clinical approach, and demonstrates the potential value proposition of Biomica

Management

Dr. Elran Haber, CEO

- Previously served as the CEO of Therapix Biosciences (Nasdaq, TASE: TRPX), leading the company to a successful IPO on Nasdaq, and advancing the company's programs to clinical stage
- Spent more than 10 years as Chairman and board member of several privately held, and publicly traded, companies
- Served in senior executive roles in various life science companies and a private investment firm
- Holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel

Prof. Yehuda Ringel, CSO

- Chief Division of Gastroenterology and Hepatology at Meir Medical Center, Israel
- Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals
- Has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and an expert on IBS and functional motility disorders
- Recipient of several prestigious awards
- MD from Technion Institute of Technology, Israel

Dr. Shiri Meshner, VP of R&D

- Previously served as the head & principal investigator of the Dead Sea microbiology lab in the Dead Sea-Arava Science Center
- Spent over 5 years working in the pharma industry both in the US and in Israel (OSI pharmaceuticals and Teva pharmaceuticals)
- Holds a PhD in systems microbiology from the Department of Physics of Complex Systems at The Weizmann Institute

Board of Directors

Mr. Ofer Haviv, Chairman

- Serves as Evogene's (Nasdaq: EVGN), President and CEO as of late 2004. Prior to that he held the positions of Evogene's COO and CFO and was involved in the spin-off from Compugen
- Served as a Director of Finance and Treasurer at Compugen (NASDAQ: CGEN), includes two private placements and an IPO on NASDAQ

Mr. Doron Ben Ami, Director

- A seasoned executive with more than 20 years of management experience in the multinational biotech industry
- Served as Head of the Eastern Europe and Israel region at Merck (MSD), Managing Director of MSD Israel and previously as the General Manager of Lundbeck in Israel

Dr. Kinneret Savitsky, Director

- A seasoned Biopharma executive
- Serves as the CEO of FutuRx Ltd., the Israeli Biotechnology accelerator established by OrbiMed, Johnson & Johnson Innovation, JJDC and Takeda Pharmaceutical
- Currently serves as a Chairperson and Board member at number of privatly held healthcare/pharma companies
- Served as the CEO of BioLineRx Ltd. (Nasdaq: BLRX)

Prof. Yehuda Ringel, Director

Scientific Advisory Board & Advisors

Prof. Yehuda Ringel

Chief Division of Gastroenterology and Hepatology at Meir Medical Center, Israel. Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals.

Prof. Willem M De Vos

Professor and Chair of Microbiology at Wageningen University, the Netherlands and Professor of Human Microbiomics at the University of Helsinki, Finland.

Prof. R. Balfour Sartor

Serves as the Midget Distinguished Professor of Medicine, Microbiology and Immunology and Director of the Multidisciplinary IBD Center at the University of North Carolina, Chapel Hill.

Prof. James Versalovic

Pathologist-In-Chief at Texas Children's Hospital and Director of Texas Children's Microbiome Center, Professor and Vice Chair of Pathology & Immunology at Baylor College of Medicine.

Prof. David Rubin

Section chief of gastroenterology, hepatology, and nutrition at University of Chicago Medicine.
Chair-elect of the National Scientific Advisory Committee of the Crohn's and Colitis Foundation.

Dr. Ravid Straussman

Principle investigator of the Tumor microenvironment, tumor microbiome and resistance to anti-cancer therapy lab at the Weizmann Institute of Science, Israel.

SUMMARY

- Human Microbiome based therapeutics is a rapidly growing space, represents a multi $Bn market opportunity
- Biomica develops innovative microbiome-based therapeutics utilizing a dedicated computational predictive biology tools
- Biomica's computational tools have been specifically developed to allow the processing of large amounts of data to obtain high-resolution mapping of microbial profiles to deliver optimized drug candidates
- Focus on high-value clinical programs for the development of therapies for antibiotic resistant bacteria, Immuno-Oncology and microbiome-related gastrointestinal (GI) disorders.
- Experienced Management Team, Board of Directors and world class Scientific Advisory Board

BIOMICA

www.biomicamed.com

13 Gad Feinstein St., Park Rehovot
P.O.B 2100 Rehovot 76121, Israel

info@biomicamed.com

T. +972 8 9311900/1
F. +972 8 9466724

Exhibit 99.4


CANONIC
Cultivated by Science
Company Presentation
April 2021
A subsidiary of evogene
DECODING BIOLOGY

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.


INTRODUCTION

Company Overview

- Canonic was established in early 2019 as a **spin-off from Evogene** (NASDAQ, TASE: EVGN) focusing on medical cannabis
- Canonic has an **exclusive license** to develop cannabis varieties using Evogene's state-of-the-art **computational genomics technology**
- **Distinct advantage to tackle market challenges** by mapping, decoding and stabilizing the cannabis genetics
- **Breeding infrastructure** among the biggest in Israel and unique proprietary knowhow
- First generation varieties expected to produce **premium quality products** to connect the company with the patients and market
- **Product launch expected at early 2022-** the company is evaluating its first-generation varieties with licensed growers and in preparation for commercial cultivation
- Company products expected to be launched under the "**Canonic" brand** in Israel followed by the EU and NA with local partners
- Next generation products expected to focus on 2 major medical indications, **pain and inflammation** that are >60% of the medical market*

*Company estimate, based on data published by Israeli Health Ministry regarding number of medical cannabis users in Israel

OUR VISION

Commercialize effective, precise and stable medical cannabis products, based on novel cannabis varieties, for optimized therapeutic impact

We are here because genetics can make cannabis much more effective

Team

Dr. Arnon Heyman
CEO

Dr. Inbal Dangoor
VP R&D

Guy Adler
Product manager & business development

Ido Zinger
Propagation

Elad Bonjak
Technician

Yoanatan Wegman
Agronomist

Dr. Michi Brog
Plant breeder

CANONIC

Directors and Advisory Board

Board of directors

Ofer Haviv
Chairman of the board
Evogene President & CEO

Raanan Cohen
Business strategy
Former CEO Koor industries

Dorit Kreiner
Finance
Evogene CFO

Advisors

Dr. Yossi Tam
Cannabinoid clinical research
Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew university

Dr. Yariv Brotman
Plant metabolic pathways
Ben Gurion University & Max Planck institute of Molecular Plant Physiology

Shai Leviatov
Plant breeding
Commercial varieties breeding for more than 30 years in top leading multinational seeds companies

Adv. Itay Rosenfeld
Business strategy
Cannabis entrepreneur and former BOD member of Intelicanna (TLV: INTL)

Nirit Elyovich
Marketing strategy
Senior marketing specialist with over 20 years of B2C experience in various markets

Global Cannabis Market

Medical cannabis is >60% of the global market



CANONIC

Market Challenges & The Opportunity

THE CHALLENGES

STABILITY

Substantial variations within varieties produce inconsistent products and therefore inconsistent results

YIELD

More active compounds and income per sq foot

SPECIFICITY

Significant knowledge gap prevents matching active compounds to medical indications

THE OPPORTUNITY- With state-of-the-art plant genomic expertise Canonic can solve major market challenges

From Plant Genetics – To Medical Cannabis Products

Plant genetic knowhow is the basis for development of **premium Cannabis varieties**

Premium varieties lead to **novel medical Cannabis products** addressing market challenges


Technology

Proven Capabilities Along The Development Value Chain

The only company in Israel holding computational genomics capabilities and the full plant infrastructure to execute

Large genetic & breeding collections	State of the art data collection tools	**State of the art computational genomics**	Advanced-breeding facility	Fully equipped labs & tissue culture rooms	Propagation farm
					

CANONIC

The Genomic Power – Trait Improvement

The potential – improving plant traits through genomic elements

Example- wild corn went through numerous genomic changes before it became a commercial crop. Today corn is the food market basis for the entire world.

The challenge:

How can we connect genes to traits?

How can we shorten the development time?

Wild Maze

Cultured Maze

When Genomics Meets Computational Biology



Computational Genomics

Combining deep scientific knowhow with Big Data and AI technology to tailor the plant genetic for improvement of plant traits and development of unique cannabis products

Big Data & AI transforming Data to Knowhow

Plant genomics database with >10^9 data points on > 200 plants

Proprietary Cannabis genomic & chemical data on > 800 lines from 50 sources

Pre-clinical data

BIG DATA

AI

Cannabis tailored unique database

Computational genomics tools

MetaYield+
Precise+

Canonic Holds Unique Knowhow in Plant Genetics

Controlling genetics › controlling plant traits › improving cannabis type & quality

Plant traits under development at Canonic



CANONIC


PRODUCTS
CANONIC

Variety Families Under Development

MetaYield+

Stable enhancement of **total plant** compounds.

Focus on **agronomic** and **consumer** traits.

Increased compounds per plant
[e.g. Increased trichomes prevalence]

Increased compounds per area
[e.g. Dwarf & early flowering]

First product launch expected in 2022

Precise+

Stable enhancement of **specific active** compounds

Focus on **therapeutic** traits

Medical indication focus
[e.g. Pain & Inflammation]

Compound profile focus
[e.g. CBG, CBC]

First product launch expected in 2023

MetaYield+ : First Commercial Varieties

Canonic expects to commercialize its first varieties during 2022

Variety name- NOA series

High THC | High yield | Big inflorescence | Dense trichomes

Status: pre-commercial

Relevant market segment: T20/C4**

Expected launch in Israel: early 2022

Target markets: Israel ($250M*) EU ($500M*)

*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.
** THC 20%, CBD 4%

Precise+ : Next Generation Varieties

Product 1

- **Indication:** Inflammation
- **Pre-clinical study:** Hadassah medical center
- **Status:** product development
- **Expected launch in Israel:** 2023
- **Target market size:* Israel** $115M, **EU** $300M

Product 2

- **Indication:** Pain
- **Pre-clinical study:** Migal research center
- **Status:** product development
- **Expected launch in Israel:** 2023
- **Target market size:* Israel** $280 M, **EU** $750M

Hadassah Medical Center

MIGAL Galilee Research Institute LTD.

*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.

Collaboration With Tikun Olam-Cannbit as Part of Precise+ Product Development

Precise+

Stable enhancement of **specific** **active** compounds

Focus on **therapeutic** traits

Medical indication focus

Compound profile focus

CANNBIT CANONIC

Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products

Collaboration to combine the cannabis expertise of both parties, including extensive clinical and related data of Cannbit and leading computational predictive biology capabilities and genomic data of Canonic

Tel-Aviv and Rehovot, Israel – February 24th, 2021 – Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. (TASE: TKUN), a leading medical cannabis company, and Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis products, today announced that they have entered into a collaboration agreement for the development of novel medical cannabis products.


Business model

Cannabis Value Chain

FROM GENOMICS TO PRODUCT

ACTIVITY	Varieties Development	Seeds & Seedling Production	Cannabis Cultivation	Packaging, Extraction & Formulation	Distribution	Sales & Marketing	Patients
	R&D Facilities	Propagation Farms	Cultivators	Manufacturers	Regional Distributors	Pharmacies & Web Platforms	

Canonic in the Cannabis Value Chain

Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain

ACTIVITY

CANONIC — Varieties Development

Active R&D Facilities

CANONIC — Seeds & Seedling Production

Active Propagation Farm

Service providers

Cannabis Cultivation

Cultivators

agreement signed

TelCann

Extraction & Formulation

Extraction & Formulation

agreement signed

TIKUN OLAM MEDICAL CANNABIS

Distribution

Regional Distributors

agreement signed

CANONIC — Sales & Marketing

Pharmacies & Web Platforms

Patients

Value Creation – Short Term Milestones

2021- pre commercial

- **MetaYield** –
  - reach 1st commercial variety;
  - sign production and distribution agreements in anticipation for commercialization in 2022
- **Precise** - identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation

2022- commercial

- **MetaYield** - commercial launch and initial sales of 1st product in Israel
- **Precise** - reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023

Anticipated Commercial Milestones (5y)



CANONIC


Summary

Cutting-Edge Technology Addressing Market Challenges

Stability

Specificity

Yield

Reduced genetic variation

Diverse extracts for pre-clinical assays

Increased trichome density

CANONIC

Summary

Canonic aims to develop novel varieties through a unique genomic approach and **commercialize medical grade Cannabis**

Product launch expected in 2022

Exclusive access to computational genomics technology

Infrastructure in place – from seed to sale

Commercial partners in place for cultivation, production and distribution (IL)

Leading **academic partnerships** for unique variety development


CANONIC
Cultivated by Science
THANK YOU

Exhibit 99.5

lavie bio
better by nature

Forward looking statement

This presentation contains "forward-looking statements" relating to future events, and Lavie Bio (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

The fork influences the farm

Consumer preferences drive change and impact how food is grown

Healthier food

Sustainable environment

Productive agriculture

Better value


Farmers around the world invest*
$200B+
annually in ag inputs to protect
and nurture their crops
$135B
Chemical
Fertilizers
$55B
Crop protection
chemicals
$8B
Ag-Biological
* Company estimations
4

The Ag-Biologicals opportunity

Driving healthier produce, sustainability and productive agriculture

Driving crop productivity

- New modes of action
- Protect from resistance evolvement
- Safe

Faster GTF (go to field)



Company estimations

Fastest growing ag. inputs segment



*Source: MarketsandMarkets, industry publications

The Ag-Biologicals untapped potential

	Crop Protection & Fertilizers	Ag-Biologicals Today
Sustainability	+	+++
Efficacy	+++	++
Consistency	+++	+
Commercial viability	+++	+

* Company estimates

Our Mission

lavie bio

Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products

The Ag-Biologicals Opportunity

	Crop Protection & Fertilizers	Ag-Biologicals Today	Next gen Ag-Biologicals
Sustainability	+	+++	+++
Efficacy	+++	++	+++
Consistency	+++	+	+++
Commercial viability	+++	+	+++

* Company estimates

The Microbiome:

Billions of microbes matter!



Integral to plant ecosystems



Nature's largest 'function bank'



'Live Engine' producing in the field

Biology Driven Design platform

The microbiome OS

MicroBoost AI → Enabled by MicroBoost AI and Taxon platforms ← TAXON Biosciences

Discovery

Billions > Promising few

Optimization

Promising few > products

Application

Products > Yield protection

Decoding the natural diversity of genetic functionality

Limitless possibilities, designs and functions:
Go as far as imagination takes you

Nature's functional diversity

Proprietary Function Hub

Function based design

Biology Driven Design platform

BDD Platform

Holistic AI driven platform harnessing the power of genomics

Unlocking the complex microbiome interactions:

Amplify the positive	Eliminate the negative	Retrieve the lost

→ **Diversity**

→ **System Modelling**

→ **Genomic Prism**

→ **Function Hub**



→ **Design**

Path to market

Lavie Bio Product

Direct model

- Non – consolidated segments
- Commercialization through channels
- Revenues from sales

Lavie Bio product & tech inside

Indirect model

- Consolidated segments
- Commercialization through partner's channels
- Revenues from R&D / Milestones and royalties

Lavie Bio tech inside

Indirect model

- Precision Optimization of 3rd party's products
- Short time to market
- Revenues from sales or R&D / Milestones and royalties

Product pipeline

Product Program	Product focus	Target market*	Potential expansion*	Discovery	Pre-Development	Development Stage 1	Development Stage 2	Pre-Commercialization	Product *
Bio-Stimulants									
LAV 211, 212 Bio-stimulants 1	Seed treatment, Spring Wheat North America	25M ACRES wheat North America	500M ACRES						2022
LAV 213, 218 Bio-stimulants 2	Seed treatment Corn North America Europe	120M ACRES corn US, EU	180M ACRES						>2025
Bio-Pesticides									
LAV 311, 312 Fruit rots	Foliar F&V Europe North America	>$200M grapes chemicals usage	+$150M Additional F&V						2024
LAV 321, 322 Downey mildew	Foliar F&V Europe North America	>$350M grapes chemicals usage	+$150M Additional F&V						2025
LAV 431, 432 Seedling disease (Pythium)	Seed Treatment, Corn, soy, F&V North America Europe	>$500M	<$200M						>2025
LAV 441, 442 Bio-Insecticides	Seed Treatment, Corn, foliar soy North America Europe	>$1.5B existing traits and chemicals market	<$500M						>2025

* Company estimations

LAV 211

Bio-stimulants driving yield advantage

1st focus market – Spring Wheat, 25M acres (ND, MT, West Canada)

Expected 1st sales in 2022

- Up to **25% yield** gain
- **>$20** add value per acre
- **Better** than ag-biologicals benchmarks tested



LAV 312

Bio-fungicides against Botrytis & fruit rots

High value markets, expected 1st sales in 2024

Better than ag-biologicals and comparable to chemicals benchmarks tested



Different letters indicate significant differences between groups (p values<0.05)

Established ‘End to End’ capabilities

Strategic shareholders

CORTEVA agriscience

evogene

TAXON Biosciences

Micro Boost AI

28%

72%

lavie bio

We've got the right team to nurture it

Management Team

Ido Dor | CEO

Leadership experience of 20+ years in business development, sales and channel management

Dorit Kriener | CFO

20+ years of experience in corporate finance, public and private fundraising, strategy and accounting management

James Presnail | COO

Extensive development and product expertise in the ag-biologicals field for 30+ years – led introductions of 5 commercials products

Michael Ionesco | VP Research

Innovative research leader with deep biotechnology, big data and informatics expertise

Amir Bercovitz | **VP Development**

Extensive development and product expertise in the ag-biologicals field for 30+ years – led introductions of 5 commercials products

Board of directors

Ofer Haviv

Chairman of the board Evogene CEO

Frederic C. Beudot

Global Portfolio Leader for Biologicals at Corteva Agriscience™

Kristian Bjorneboe

Seasoned business development leader

Trevor Thissen

Senior agriculture executive, experienced in marketing, sales, and go-to-market

Milestone Roadmap

2021

- LAV211 product pre commercialization phase
- Commercial team and GTM
- Advance LAV 311 / 312 product development

2022

- First product launch for LAV211 ($sales)
- Product advancement in regulation process for LAV311 / LAV312
- Strategic and GTM collaborations

2023-2024

- Product portfolio expansion – product launches ($sales)
- Precision Optimization product – Pre-Launch
- Established market channels

Market opportunity

Lavie Bio is uniquely positioned to improve how food is grown, protected & consumed

Farm

Post harvest

Consumer

Thank you!